Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC

BACKGROUND: Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are widely used for EGFR mutated non-small-cell lung cancer (NSCLC) patients, tumor sample availability and heterogeneity of the tumor remain challenging for physicians’ selection of these patients. Here,...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Wu, Xuan, Liang, Wenhua, Hou, Xue, Lin, Zhong, Zhao, Hongyun, Huang, Yan, Fang, Wenfeng, Zhao, Yuanyuan, Wu, Jingxun, Yang, Yunpeng, Xue, Chong, Hu, Zhihuang, Zhang, Jing, Zhang, Jianwei, Ma, Yuxiang, Zhou, Ting, Qin, Tao, Zhang, Li
Format: Artigo
Langue:Inglês
Publié: Dove Medical Press 2013
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3818102/
https://ncbi.nlm.nih.gov/pubmed/24204163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S51887
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires